<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Cystic fibrosis: Antibiotic therapy for chronic pulmonary infection
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Simon, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            James F Chmiel, MD, MPH
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Alison G Hoppin, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Oct 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cystic fibrosis (CF) is a multisystem disorder caused by pathogenic variants in the CF transmembrane conductance regulator (
         <em>
          CFTR
         </em>
         ) gene, located on chromosome 7 [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         .)
        </p>
        <p>
         Pulmonary disease remains the leading cause of morbidity and mortality in patients with CF [
         <a href="#rid2">
          2
         </a>
         ]. One of the major drivers of CF lung disease is infection [
         <a href="#rid3">
          3
         </a>
         ]. The approach to treating infection in CF is multifaceted, involving antibiotics, chest physiotherapy, inhaled medications to promote secretion clearance, and antiinflammatory agents. Undoubtedly, improved use of antibiotics is responsible for a substantial portion of the increased survival that has occurred in patients with CF  (
         <a class="graphic graphic_figure graphicRef61930" href="/z/d/graphic/61930.html" rel="external">
          figure 1
         </a>
         ).
        </p>
        <p>
         The use of antibiotics to treat chronic pulmonary infections in CF will be reviewed here. Treatment of acute pulmonary exacerbations and other aspects of pulmonary disease in CF are discussed in separate topic reviews:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/129117.html" rel="external">
          "Cystic fibrosis: Management of advanced lung disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/118899.html" rel="external">
          "Cystic fibrosis: Treatment with CFTR modulators"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6369.html" rel="external">
          "Cystic fibrosis: Clinical manifestations of pulmonary disease"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The diagnosis and pathophysiology of CF and its manifestations in other organ systems are also discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6367.html" rel="external">
          "Cystic fibrosis: Clinical manifestations and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6368.html" rel="external">
          "Cystic fibrosis: Genetics and pathogenesis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5882.html" rel="external">
          "Cystic fibrosis: Nutritional issues"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5885.html" rel="external">
          "Cystic fibrosis: Assessment and management of pancreatic insufficiency"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5858.html" rel="external">
          "Cystic fibrosis: Overview of gastrointestinal disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/99126.html" rel="external">
          "Cystic fibrosis: Hepatobiliary disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14544.html" rel="external">
          "Cystic fibrosis-related diabetes mellitus"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          PATHOGENS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most patients with CF develop chronic bacterial infection within the airways  (
         <a class="graphic graphic_table graphicRef55018" href="/z/d/graphic/55018.html" rel="external">
          table 1
         </a>
         ). The prevalence of each bacterial type varies with the age of the patient  (
         <a class="graphic graphic_figure graphicRef74073" href="/z/d/graphic/74073.html" rel="external">
          figure 2
         </a>
         ) and geographic region of the United States, with methicillin-resistant
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         (MRSA),
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         , and nontuberculous mycobacteria (NTM) being more prevalent in the South [
         <a href="#rid4">
          4
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9942753">
         <span class="h2">
          Pseudomonas aeruginosa
         </span>
         <span class="headingEndMark">
          —
         </span>
         For reasons that are poorly understood, the CF airway is particularly susceptible to
         <em>
          P.
         </em>
         <em>
          aeruginosa
         </em>
         , with infection occurring as early as the first year of life. The prevalence of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         increases with age, such that more than 60 percent of adults are chronically infected [
         <a href="#rid2">
          2
         </a>
         ]. Of note, the prevalence and incidence of new chronic infections appears to have decreased among adolescents and adults in the United States [
         <a href="#rid5">
          5-7
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3142.html" rel="external">
          "Epidemiology, microbiology, and pathogenesis of Pseudomonas aeruginosa infection"
         </a>
         .)
        </p>
        <p>
         Chronic infection with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is an independent risk factor for accelerated loss of pulmonary function and decreased survival [
         <a href="#rid8">
          8,9
         </a>
         ]. Transmissible strains of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         have been detected in CF populations in Europe, Australia, and Canada, and some of these strains are associated with a worse prognosis compared with non-transmissible strains [
         <a href="#rid10">
          10,11
         </a>
         ]. Protocols for early detection and eradication have had considerable success. (See
         <a class="local">
          'Pseudomonas aeruginosa'
         </a>
         below and
         <a class="local">
          'Infection prevention and control'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7028176">
         <span class="h2">
          Staphylococcus aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         <em>
          S.
         </em>
         <em>
          aureus
         </em>
         is the bacterial pathogen most frequently identified in respiratory secretions of CF infants and children [
         <a href="#rid2">
          2
         </a>
         ]. It remains a significant pathogen throughout adulthood. In children under six years of age infected with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         , coinfection with
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         has an independent and additive effect on airway inflammation [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7028183">
         <span class="h2">
          Methicillin-resistant Staphylococcus aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         MRSA has become more prevalent in the CF population, increasing from 9.2 percent in 2002 to 24.6 percent in 2019 [
         <a href="#rid2">
          2
         </a>
         ]. Regarding the role of MRSA in patients with CF:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         One study reported that acquisition of MRSA was associated with a slightly greater rate of decline in pulmonary function (as measured by forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ]) in children but not in adults [
         <a href="#rid13">
          13
         </a>
         ], while another study reported that MRSA had no effect on the rate of FEV
         <sub>
          1
         </sub>
         decline [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A study of nearly 20,000 CF patients in the United States found that MRSA was associated with 1.3 times the risk of death compared with individuals never infected with MRSA [
         <a href="#rid15">
          15
         </a>
         ]. Multivariate analysis showed that MRSA was an independent risk factor whose effect could not be explained by its association with other known risk factors including age, sex, diabetes, pancreatic status, FEV
         <sub>
          1
         </sub>
         at baseline, and socioeconomic status or coinfection with
         <em>
          Burkholderia
         </em>
         <em>
          cepacia
         </em>
         complex or
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         .
        </p>
        <p>
        </p>
        <p>
         Early detection and eradication of MRSA has shown some promise. (See
         <a class="local">
          'Methicillin-resistant Staphylococcus aureus'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3649295602">
         <span class="h2">
          Burkholderia cepacia complex
         </span>
         <span class="headingEndMark">
          —
         </span>
         Advances in bacterial genetics have revealed that
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         , which was originally thought to be a single species, is now known to constitute multiple separate species, collectively known as
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         complex [
         <a href="#rid16">
          16
         </a>
         ]. The species most commonly isolated from the sputum of CF patients are
         <em>
          B
         </em>
         .
         <em>
          multivorans
         </em>
         and
         <em>
          B
         </em>
         .
         <em>
          cenocepacia
         </em>
         [
         <a href="#rid6">
          6,7,17
         </a>
         ]. The original strain identified many years ago retains the species name,
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         , but is rarely found in patients with CF.
         <em>
          B
         </em>
         .
         <em>
          gladioli
         </em>
         , another
         <em>
          Burkholderia
         </em>
         species not belonging to the
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         complex, is the third most frequent
         <em>
          Burkholderia
         </em>
         species identified in respiratory secretions of CF patients.
        </p>
        <p>
         Chronic infection with
         <em>
          B
         </em>
         .
         <em>
          cenocepacia
         </em>
         complex bacteria is associated with an accelerated decline in pulmonary function and shortened survival in CF [
         <a href="#rid18">
          18
         </a>
         ]. Much of the worse outcome is attributable to the highly transmissible ET-12 (Edinburgh/Toronto-12) strain [
         <a href="#rid19">
          19
         </a>
         ]. Lung transplantation in patients infected with
         <em>
          B
         </em>
         .
         <em>
          cenocepacia
         </em>
         often leads to recurrent and often severe infection with poor outcomes [
         <a href="#rid20">
          20,21
         </a>
         ], causing most transplantation centers to consider it a relatively strong contraindication to transplantation [
         <a href="#rid22">
          22
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1395.html" rel="external">
          "Bacterial infections following lung transplantation", section on 'Burkholderia cepacia'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1313835068">
         <span class="h2">
          Nontuberculous mycobacteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         NTM can be isolated from the sputum in 10 to 20 percent of patients with CF, with increasing prevalence with age and substantial geographic variation [
         <a href="#rid2">
          2,23-25
         </a>
         ]. The incidence of NTM-positive cultures has increased substantially over decades in populations with CF as well as in the general population.
         <em>
          Mycobacterium
         </em>
         <em>
          avium
         </em>
         complex is identified in up to 75 percent of these patients. The other frequently identified pathogen is
         <em>
          Mycobacterium
         </em>
         <em>
          abscessus
         </em>
         complex (which includes the subspecies
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         ,
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         <em>
          bolletii
         </em>
         , and
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         <em>
          massiliense
         </em>
         ) and has become more common than
         <em>
          M
         </em>
         .
         <em>
          avium
         </em>
         complex in some populations [
         <a href="#rid26">
          26-30
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5344.html" rel="external">
          "Epidemiology of nontuberculous mycobacterial infections"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/5343.html" rel="external">
          "Microbiology of nontuberculous mycobacteria"
         </a>
         .)
        </p>
        <p>
         The clinical implications of detecting NTM in sputum samples of patients with CF are quite variable. NTM may be transiently, intermittently, or continuously present in patients without apparent clinical sequelae. However, on average, the rate of decline in FEV
         <sub>
          1
         </sub>
         is greater in patients infected with
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         than a control population [
         <a href="#rid28">
          28,31
         </a>
         ]. The impact on lung function appears to be less in patients with other species of NTM [
         <a href="#rid26">
          26,28,32
         </a>
         ]. A subset of patients develop progressive inflammatory lung damage, known as NTM pulmonary disease, for which specific treatment is warranted in selected cases [
         <a href="#rid32">
          32
         </a>
         ]. (See
         <a class="local">
          'Nontuberculous mycobacteria'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H7493970">
         <span class="h2">
          Other pathogens
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other pathogens have been identified in respiratory secretions of CF patients, with varying prevalence  (
         <a class="graphic graphic_table graphicRef55018" href="/z/d/graphic/55018.html" rel="external">
          table 1
         </a>
         and
         <a class="graphic graphic_figure graphicRef74073" href="/z/d/graphic/74073.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid2">
          2,6,7
         </a>
         ]. These include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nontypeable
         <em>
          Haemophilus
         </em>
         <em>
          influenzae
         </em>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Stenotrophomonas
         </em>
         <em>
          maltophilia
         </em>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Achromobacter
         </em>
         species
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <em>
          Aspergillus
         </em>
         species
        </p>
        <p>
        </p>
        <p>
         Other species identified in the respiratory secretions of occasional CF patients include non-
         <em>
          Cepacia
         </em>
         complex
         <em>
          Burkholderia
         </em>
         species (
         <em>
          Burkholderia
         </em>
         <em>
          gladioli
         </em>
         and
         <em>
          Burkholderia
         </em>
         <em>
          pseudomallei
         </em>
         ),
         <em>
          Ralstonia
         </em>
         species, and
         <em>
          Pandoraea
         </em>
         species. Although these organisms are identified more frequently than in the past, this may be due to refinements in microbial culture techniques and the use of molecular genetic methods that separate these organisms into an ever-expanding taxonomy of bacterial pathogens, rather than increasing prevalence [
         <a href="#rid33">
          33
         </a>
         ]. Furthermore, nonculture-based molecular genetic techniques have identified microorganisms in respiratory secretions of patients with CF that were previously unrecognized as being present [
         <a href="#rid34">
          34
         </a>
         ]. Both culture-based and genetic methods have revealed high densities of anaerobic bacteria in respiratory secretions from CF patients [
         <a href="#rid35">
          35-37
         </a>
         ]. Investigations are ongoing to determine the role of this complex microbiota in driving pulmonary exacerbations and disease progression.
        </p>
        <p class="headingAnchor" id="H7025018">
         <span class="h1">
          CONSEQUENCES OF CYSTIC FIBROSIS LUNG INFECTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once established in the CF airway, many of the above organisms are difficult to eliminate. However, definitive studies have demonstrated that
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection can be eradicated if detected early and treated. The same may be true for methicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         (MRSA), but this will require further study. (See
         <a class="local">
          'Prevention and eradication'
         </a>
         below.)
        </p>
        <p>
         Although chronic infection of the CF airway is sometimes referred to as "airway colonization," the presence of many of these bacteria is not benign:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Chronic infection with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is an independent risk factor for accelerated loss of pulmonary function and decreased survival, and conversion of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         to the mucoid phenotype worsens prognosis. (See
         <a class="local">
          'Pseudomonas aeruginosa'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection with
         <em>
          B
         </em>
         .
         <em>
          cenocepacia
         </em>
         connotes an even worse prognosis than chronic infection with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         . (See
         <a class="local">
          'Burkholderia cepacia complex'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infection with MRSA is also associated with worse survival. (See
         <a class="local">
          'Methicillin-resistant Staphylococcus aureus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A subset of patients with nontuberculous mycobacteria (NTM) infection, especially
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         , develop progressive inflammatory lung damage known as NTM pulmonary disease, which is associated with worsening pulmonary function and can be difficult to eradicate. (See
         <a class="local">
          'Nontuberculous mycobacteria'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p>
         Several mechanisms may contribute to the persistence of bacteria in CF patients despite aggressive treatment including poor penetration of antibiotics into purulent airway secretions, native or acquired antibiotic resistance, CF-related defects in mucosal defenses, and/or biofilms produced by the bacteria that may render antibiotics ineffective or interfere with host defenses.
        </p>
        <p class="headingAnchor" id="H7028282">
         <span class="h1">
          PERIODIC SURVEILLANCE CULTURES
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest performing bacterial cultures of expectorated sputum or throat swabs at least every three months during routine clinic visits, consistent with guidelines from the Cystic Fibrosis Foundation (CFF) [
         <a href="#rid38">
          38-40
         </a>
         ]. We also suggest performing cultures at least annually for nontuberculous mycobacteria (NTM) [
         <a href="#rid24">
          24
         </a>
         ] and fungi for patients who can spontaneously expectorate sputum. More frequent cultures are appropriate for patients with deteriorating respiratory status or who are not responding adequately to standard treatment for a pulmonary exacerbation. We use the culture results as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To monitor for the acquisition of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         , which we treat with an eradication protocol (see
         <a class="local">
          'Pseudomonas aeruginosa'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To initiate chronic treatment with inhaled antibiotics for patients chronically infected with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         (see
         <a class="local">
          'Inhaled antibiotics'
         </a>
         below)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To guide selection of antibiotics in the event of an acute exacerbation (see
         <a class="local">
          'Pseudomonas aeruginosa'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Respiratory secretion cultures'
         </a>
         )
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         To initiate evaluation and possible treatment of patients who are newly positive for NTM (see
         <a class="local">
          'Nontuberculous mycobacteria'
         </a>
         above)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H431170060">
         <span class="h1">
          PREVENTION AND ERADICATION
         </span>
        </p>
        <p>
         Once a patient becomes chronically infected with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         , treatment strategies are unsuccessful at eradicating it. Variable success has been reported for methicillin-resistant
         <em>
          S. aureus
         </em>
         (MRSA). Early studies of highly effective CF transmembrane conductance regulator (CFTR) modulators have reported inconsistent results regarding whether they reduce the acquisition and prevalence of CF pathogens [
         <a href="#rid41">
          41-43
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2457284300">
         <span class="h2">
          Pseudomonas aeruginosa
         </span>
         <span class="headingEndMark">
          —
         </span>
         Strategies to prevent
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         from chronically infecting the airways of CF patients include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Prevention of acquisition
         </strong>
         – We recommend measures to prevent transmission of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         among CF patients. (See
         <a class="local">
          'Infection prevention and control'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         We do
         <strong>
          not
         </strong>
         recommend prophylactic use of antibiotics targeting
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         or
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         in an attempt to prevent
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         acquisition [
         <a href="#rid40">
          40,44
         </a>
         ]. Clinical trials of this approach did not show benefit:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A randomized trial evaluated the effects of treating children without
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection with cycles of oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         and inhaled
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         [
         <a href="#rid45">
          45
         </a>
         ]. Three-week courses of these medications were administered every three months for three years. At the end of the three-year trial, there was no difference between rates of initial or chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection among children who had received this intervention as compared with controls.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Because
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         was often noted to infect CF patients prior to the appearance of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         , it was hypothesized that damage from
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         might cause the CF airway to be more susceptible to
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         . If so, chronic prevention or suppression of
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         infection might reduce the frequency of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         and preserve airway function [
         <a href="#rid46">
          46
         </a>
         ]. To test this hypothesis, a randomized trial of oral
         <a class="drug drug_general" data-topicid="9231" href="/z/d/drug information/9231.html" rel="external">
          cephalexin
         </a>
         was performed in young children [
         <a href="#rid47">
          47
         </a>
         ]. Cephalexin or placebo was started at the time of CF diagnosis and administered continuously for seven years. Cephalexin was successful in reducing the prevalence of
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         infection, but the incidence of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection actually increased and there was no evidence of overall clinical benefit. Furthermore, a retrospective study of registry data from the United Kingdom studied children less than approximately four years old who either did or did not receive chronic flucloxacillin [
         <a href="#rid48">
          48
         </a>
         ]. The risk of acquiring
         <em>
          Staphylococcus
         </em>
         was not reduced with chronic flucloxacillin, but the risk of acquiring
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         increased.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early eradication
         </strong>
         – We recommend using a protocol to detect and treat
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         when it is first acquired, regardless of age or whether there are associated clinical signs or symptoms [
         <a href="#rid49">
          49,50
         </a>
         ]. We perform cultures of expectorated sputum or throat swabs every three months during routine clinic visits. When
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is first detected, we treat with inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         alone (300 mg administered twice daily) for 28 days, rather than a regimen including
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         or other antibiotics. Repeat cultures should be performed within four weeks after completion of treatment. The therapy is repeated only if surveillance cultures show recurrence of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         [
         <a href="#rid51">
          51
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This practice of early eradication is supported by considerable clinical evidence and has been incorporated into the Cystic Fibrosis Foundation (CFF) clinical guidelines [
         <a href="#rid50">
          50,52
         </a>
         ]. Treatment of patients as young as one year of age [
         <a href="#rid49">
          49
         </a>
         ] with newly acquired
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         typically achieves initial eradication in 70 to 90 percent of subjects after a 28-day cycle of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         [
         <a href="#rid51">
          51-54
         </a>
         ]. The longest observational study reported that 70 percent of patients treated with an early eradication protocol remained free of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         12 months after the initial treatment (sustained eradicators) [
         <a href="#rid55">
          55
         </a>
         ]. During the following five years, 77 percent of sustained eradicators remained free of chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         and only 17 percent developed mucoid species. There were minimal differences in clinical outcomes during this follow-up period, but longer studies may be needed to detect such differences. Other trials found no additional benefit for longer duration of inhaled tobramycin [
         <a href="#rid52">
          52
         </a>
         ]. The certainty and generalizability of these findings were extended by a placebo-controlled trial that included 51 children less than seven years old who received inhaled tobramycin or placebo for 28 days [
         <a href="#rid56">
          56
         </a>
         ]. Following treatment, 85 percent of patients receiving tobramycin were
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         -free compared with 24 percent of those receiving placebo, with no difference in adverse events between groups.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         There is no consensus regarding the approach to patients with newly acquired
         <em>
          P. aeruginosa
         </em>
         whose initial treatment fails to eradicate the infection. A stepwise protocol has been studied in children, in which children who failed to achieve eradication after a 28-day course of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         were given a second 28-day course of inhaled tobramycin [
         <a href="#rid57">
          57
         </a>
         ]. Those who remained positive after the second course were additionally treated with 14 days of intravenous antibiotics followed by 28 days of inhaled tobramycin. Patients who had worsening symptoms at any time during the protocol were treated with intravenous antibiotics. For those who remained asymptomatic during the study, successful eradiation was achieved in 77 percent of patients after initial treatment, 33 percent of those who progressed through step 2, and 42 percent of those who finished step 3. Given these overall favorable results and the absence of direct comparisons with other regimens, this is a reasonable approach to treating children who fail the initial attempt of eradicating a new
         <em>
          P. aeruginosa
         </em>
         infection.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Other regimens to eradicate
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         using antibiotics other than
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         have been evaluated:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Four weeks of inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         led to outcomes similar to those reported for
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         [
         <a href="#rid58">
          58
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The combination of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         was not more effective than tobramycin alone [
         <a href="#rid51">
          51,52
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The combination of inhaled
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         and oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         was similar in effect to inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         with oral ciprofloxacin [
         <a href="#rid52">
          52,54
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The combination of 28 days of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         plus 18 months of oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         resulted in greater weight gain and longer time to the first pulmonary exacerbation compared with tobramycin alone but no difference in eradication rate or other clinical outcomes [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The combination of intravenous antibiotics (
         <a class="drug drug_general" data-topicid="9226" href="/z/d/drug information/9226.html" rel="external">
          ceftazidime
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         ) and inhaled colistimethate sodium was not more effective than an oral antibiotic (
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         ) in combination with inhaled colistimethate sodium [
         <a href="#rid60">
          60
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H1246226472">
         <span class="h2">
          Methicillin-resistant Staphylococcus aureus
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic infection with MRSA is associated with declines in pulmonary function and increased risk of death, but the pathogen is difficult to eradicate once the infection is established. (See
         <a class="local">
          'Methicillin-resistant Staphylococcus aureus'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p>
         This observation has motivated development of protocols designed to eradicate both early and established MRSA infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Early
         </strong>
         <strong>
          eradication
         </strong>
         – Based on preliminary results, we believe it is reasonable to offer a treatment regimen to highly selected patients who have acquired MRSA within the previous six months, who can follow a demanding treatment protocol and who can tolerate
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         without problems from drug-drug interactions. The long-term benefits of eradication are not known.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The limited evidence supporting this approach includes several uncontrolled studies using a variety of treatment regimens that reported successful eradication of newly acquired MRSA [
         <a href="#rid61">
          61,62
         </a>
         ]. The only controlled clinical trial reported elimination of MRSA from sputum cultures at one month follow-up in 22 subjects (82 percent) in the treatment group, compared with 19 (26 percent) of those in the control group (p&lt;0.001) [
         <a href="#rid63">
          63
         </a>
         ]. However, by six months, there was no difference in the prevalence of MRSA infection between the two groups. This and one other randomized trial were included in a meta-analysis, which concluded that short-term MRSA eradication is possible, but that the long-term clinical implications are unclear [
         <a href="#rid64">
          64
         </a>
         ]. A subsequent study randomized 69 subjects to either an observation group or to a group receiving
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , sulfamethoxazole/
         <a class="drug drug_general" data-topicid="10024" href="/z/d/drug information/10024.html" rel="external">
          trimethoprim
         </a>
         , and nasal
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         [
         <a href="#rid65">
          65
         </a>
         ]. There was a trend toward eradication of MRSA in the treatment group, but only 52 percent of the subjects completed the trial, thus limiting the validity of conclusions.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         No studies have compared different eradication protocols. Nevertheless, it would be reasonable to select the regimen used in the above mentioned randomized study that showed successful eradication [
         <a href="#rid63">
          63
         </a>
         ], which consisted of oral
         <a class="drug drug_general" data-topicid="9864" href="/z/d/drug information/9864.html" rel="external">
          rifampin
         </a>
         , oral
         <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">
          trimethoprim-sulfamethoxazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9653" href="/z/d/drug information/9653.html" rel="external">
          minocycline
         </a>
         , nasal
         <a class="drug drug_general" data-topicid="9668" href="/z/d/drug information/9668.html" rel="external">
          mupirocin
         </a>
         ,
         <a class="drug drug_general" data-topicid="9244" href="/z/d/drug information/9244.html" rel="external">
          chlorhexidine
         </a>
         oral rinses and body wipes, and environmental decontamination. (See
         <a class="medical medical_review" href="/z/d/html/491.html" rel="external">
          "Rifamycins (rifampin, rifabutin, rifapentine)", section on 'Drug interactions'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Eradication of chronic infection
         </strong>
         – Combined oral, inhaled, and topical antibiotics have been tested for their ability to eradicate chronic MRSA infection from patients with CF. In a randomized study, subjects with chronic MRSA infection received either inhaled
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         or placebo for 28 days [
         <a href="#rid66">
          66
         </a>
         ]. Both groups received oral and topical anti-MRSA antibiotics and undertook environmental cleaning to limit MRSA re-exposure. The rate of MRSA eradication one month after treatment, the primary endpoint, was 20 percent in both groups.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H3108068299">
         <span class="h1">
          CHRONIC PULMONARY INFECTION (
          <i>
           PSEUDOMONAS
          </i>
          AND
          <i>
           BURKHOLDERIA
          </i>
          SPP)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         or
         <em>
          B
         </em>
         .
         <em>
          cepacia
         </em>
         complex bacteria become established in the airways of a patient with CF for more than a few months, the organisms usually persist for years despite aggressive attempts at eradication. Chronic treatment with inhaled antibiotics helps to reduce the
         <em>
          Pseudomonas
         </em>
         bacterial burden and thus lessen its impact [
         <a href="#rid67">
          67
         </a>
         ]. Because most classes of antibiotics that show in vitro activity against
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         are ineffective when administered orally, delivery by inhalation presents an attractive alternative to intravenous administration. Unfortunately, there are no chronic treatment regimens directed at established
         <em>
          Burkholderia
         </em>
         species infections that have been shown to improve outcomes.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h2">
          Inhaled antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We recommend chronic treatment with cyclic inhaled antibiotics for patients with chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection. Our approach to selecting the regimen is described below, followed by the evidence and other considerations for different types of aerosolized antibiotics.
        </p>
        <p>
         We use the following approach to prescribing inhaled antibiotics for patients with chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobramycin
         </strong>
         – Inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is our first-line choice because of the extensive information supporting the efficacy of tobramycin and its good safety record following many years of use [
         <a href="#rid39">
          39,40,44,68
         </a>
         ]. The standard inhalation solution is given as a 300 mg dose, administered by nebulizer twice daily for 28 days, alternating with 28 days off treatment. A powdered form is also available. But, of note, there is growing concern that the efficacy of inhaled tobramycin may be reduced in patients on chronic oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         . (See
         <a class="local">
          'Oral azithromycin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aztreonam
         </strong>
         <strong>
          lysine
         </strong>
         – Inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         lysine can be used as an alternative to inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         in selected patients. The dose is 75 mg by inhalation three times daily for 28 days, alternating with 28 days off treatment. (See
         <a class="local">
          'Inhaled aztreonam lysine'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         In our practice, we prescribe
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         particularly when:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The patient does not tolerate inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The patient's pulmonary status is deteriorating despite inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The patient is or may soon become pregnant, which makes aminoglycosides relatively contraindicated
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The patient is considered more likely to be adherent to inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         because of personal preference for its mode of delivery despite the need to take it three times per day compared with twice per day for
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colistin
         </strong>
         – Because no
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         preparation has been approved by the US Food and Drug Administration (FDA) for use by inhalation in the United States, we first prescribe
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and/or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         . We reserve colistin for those patients who are not doing well on these treatments or do not tolerate tobramycin and aztreonam. By contrast, in Europe, colistin is frequently used as a primary inhaled antibiotic treatment [
         <a href="#rid69">
          69
         </a>
         ]. A commonly used dose is 150 mg (colistimethate base) for children ≥10 years and 75 mg for younger children, administered twice daily for 28 days, alternating with 28 days off of treatment. (See
         <a class="local">
          'Inhaled colistin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Continuous alternating inhaled antibiotics
         </strong>
         – For patients with deteriorating pulmonary status and/or rapidly recurrent pulmonary exacerbations despite cycling between 28 days on and 28 days off of a single inhaled antibiotic, it has become common practice for clinicians to prescribe continuous treatment by
         <strong>
          alternating
         </strong>
         between two different antibiotics (eg,
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         ), each for a 28-day period.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         This approach was evaluated in a randomized clinical trial in patients with a wide range of pulmonary function (forced expiratory volume in one second [FEV
         <sub>
          1
         </sub>
         ] 25 to 75 percent predicted), in which 28 days of inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         or placebo alternated with 28-day cycles of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         [
         <a href="#rid70">
          70
         </a>
         ]. The study was terminated early because of inability to meet recruitment targets, in part because many clinicians and patients had already adopted continuously alternating therapy into their treatment regimen [
         <a href="#rid71">
          71
         </a>
         ]. The study found a trend toward reduced pulmonary exacerbation rate from continuous therapy, but it did not reach statistical significance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         A retrospective analysis of 89 patients using chronic inhaled antibiotics found that 49 were alternating between two antibiotics every four weeks, while the remaining patients were using one antibiotic with four weeks off treatment between courses. The most frequently used combinations were
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         with either
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         . The rate of change in FEV
         <sub>
          1
         </sub>
         percent predicted before initiating continuous alternating antibiotics was -0.9 points and improved to +1.1 points [
         <a href="#rid72">
          72
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Although there is insufficient evidence to support the practice of alternating inhaled antibiotics for
         <strong>
          all
         </strong>
         patients with chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection, many experts feel that it is reasonable practice for patients with advanced lung disease or those with frequent pulmonary exacerbations or accelerated decline in pulmonary status.
        </p>
        <p>
        </p>
        <p>
         We typically base the choice of inhaled antibiotics on the above considerations and clinical response, rather than on in vitro susceptibility testing. This is because antibiotic resistance as measured by in vitro susceptibility testing does not preclude a clinically beneficial response to inhaled medications. This was illustrated by studies of patients participating in clinical trials of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         or
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         that included patients infected with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         strains that would be considered antibiotic-resistant relative to drug levels that are safely attainable by parenteral administration. Subjects with these relatively resistant pseudomonal isolates were just as likely to show clinical responses to inhalational treatment as those with drug-sensitive strains [
         <a href="#rid73">
          73,74
         </a>
         ]. This is probably because antibiotic concentrations that occur in respiratory secretions following inhalation of the FDA-approved formulations far exceed the breakpoints used for determining susceptibility when the drugs are given parenterally. Furthermore, the ability of in vitro susceptibility results to predict clinical improvement for
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is in question. (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Respiratory secretion cultures'
         </a>
         .)
        </p>
        <p>
         Considerations and techniques for delivering medications by inhalation are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5737.html" rel="external">
          "Delivery of inhaled medication in children"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/552.html" rel="external">
          "Delivery of inhaled medication in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H17">
         <span class="h3">
          Inhaled tobramycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Chronic treatment with inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is a well-established first-line treatment for patients who are infected wi
         <em>
          th
         </em>
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         [
         <a href="#rid39">
          39,40,75
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing and administration:
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The standard inhalation solution of
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is 300 mg in 4 or 5 mL, administered via nebulizer twice daily, in cycles of 28 days on therapy alternating with 28 days off.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Peak serum levels following inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         in patients with normal renal function are generally &lt;2 mcg/mL, so renal and ototoxicity are rare. However, patients with impaired renal function can accumulate high serum levels of tobramycin, leading to further renal injury and ototoxicity. Annual hearing tests are suggested for all children and adults with CF who are exposed to aminoglycosides, including inhaled tobramycin [
         <a href="#rid76">
          76
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         A powdered form of
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         (tobramycin inhalation powder) can be prescribed as 112 mg contained in four capsules, inhaled twice daily using a specially designed apparatus [
         <a href="#rid77">
          77
         </a>
         ]. This preparation significantly reduces the time required to administer each dose compared with the aerosolized form [
         <a href="#rid78">
          78
         </a>
         ]. However, the frequency of cough in subjects participating in the clinical study (25.3 percent) was higher with the powdered form compared with the nebulized liquid (4.3 percent), leading to a higher rate of drug discontinuation. A subsequent study followed subjects for up to one year of treatment and reported somewhat lower frequency of cough (13.6 percent initially, with further improvement thereafter), possibly due to an alteration in the manufacturing process [
         <a href="#rid79">
          79
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Efficacy
         </strong>
         – Large trials have demonstrated that chronic treatment with inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         improves lung function, reduces acute pulmonary exacerbations, and improves quality-of-life outcomes [
         <a href="#rid80">
          80-84
         </a>
         ]. Prospective studies following patients for up to 2.5 years on aerosolized tobramycin show continuing benefit, although at the price of slightly increased bacterial resistance.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         The efficacy of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         was demonstrated in a randomized trial in 520 patients with stable CF and a wide range of pulmonary function [
         <a href="#rid80">
          80
         </a>
         ]. Twice-daily treatment with 300 mg of inhalation tobramycin solution (TOBI) was administered via jet nebulizer in cycles of 28 days on the medication followed by 28 days off for 24 weeks. Compared with a control group, subjects receiving tobramycin had a 10 percent higher FEV
         <sub>
          1
         </sub>
         at 20 weeks, a decrease in the sputum density of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         , and a 26 percent decrease in the likelihood of hospitalization during the trial. Adverse effects included slight voice alteration and tinnitus in the treatment arm. The tinnitus was mild and transient, and there was no associated hearing loss. In a two-year, open-label follow-up, ongoing use of inhaled tobramycin was associated with greater improvement in FEV
         <sub>
          1
         </sub>
         and with an increase in body mass index [
         <a href="#rid81">
          81
         </a>
         ]. Importantly, patients receiving placebo during the randomized portion of the study improved their FEV
         <sub>
          1
         </sub>
         when starting tobramycin in the open-label phase, but their FEV
         <sub>
          1
         </sub>
         levels did not catch up with those attained by subjects that began tobramycin during the randomized portion of the trial [
         <a href="#rid83">
          83
         </a>
         ]. A trend toward increased aminoglycoside resistance among sputum flora was observed among patients treated with tobramycin during the randomized portion of the trial, although the clinical relevance of this finding is unclear since the need for hospitalization or intravenous antibiotic therapy was similar for both groups and did not increase over the course of the study [
         <a href="#rid81">
          81,82
         </a>
         ]. Peak serum tobramycin concentrations averaged &lt;1 mcg/mL, and no nephrotoxicity or ototoxicity was detected. A registry study reported that receiving inhaled tobramycin solution correlated with improved survival [
         <a href="#rid85">
          85
         </a>
         ]. The association persisted when adjusted for patient demographics, lung function, comorbidities, microbiology, medical resource use, and other CF treatments, using a multivariate logistic regression model for mortality.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H24831257">
         <span class="h3">
          Inhaled aztreonam lysine
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         lysine is an alternative choice for chronic treatment of patients with chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection. It is appropriate for use in patients for whom inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is not effective or not well tolerated. Aztreonam is a monobactam antibiotic with antipseudomonal activity. The lysine salt formulation is used to avoid airway inflammation.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          Aztreonam
         </a>
         is administered using a high-efficiency nebulizer (eFlow/Altera) that delivers the dose in less than three minutes, which compares favorably with the 15 to 20 minutes required to deliver other inhaled antibiotics using conventional nebulizers. The FDA-approved package insert stipulates that aztreonam must be administered using this nebulizer, which is provided to the patient together with the first supply of drug. Although the shortened delivery time is certainly helpful to patients, this benefit is no longer unique, because of the subsequent approval of a powdered form of
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         . Also, to achieve full benefit, the aztreonam must be administered three times per day, rather than twice per day for tobramycin. Furthermore, to maintain the efficiency of the aztreonam nebulizer, the system must be carefully cleaned after each use, which adds additional time to the treatments.
        </p>
        <p>
         The efficacy of inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         lysine was demonstrated in two large clinical trials, in which patients with chronic pseudomonal lung infection were given either inhaled aztreonam lysine (75 mg) or placebo either two or three times daily for 28 days [
         <a href="#rid86">
          86,87
         </a>
         ]. All patients were older than six years, had had FEV
         <sub>
          1
         </sub>
         between 25 and 75 percent predicted, and had received 28 days of inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         prior to the trial. The group treated with inhaled aztreonam had a longer time before needing additional antipseudomonal antibiotics (92 days) compared with those given placebo (71 days) [
         <a href="#rid86">
          86
         </a>
         ]. Furthermore, patient-reported respiratory symptom scores, FEV
         <sub>
          1
         </sub>
         , and
         <em>
          Pseudomonas
         </em>
         density in sputum samples also improved in the group given aztreonam. In an open-label follow-up study, 271 of the participants in these trials were given aztreonam by inhalation either two or three times per day for 28 days, followed by 28 days off treatment, for up to nine cycles [
         <a href="#rid88">
          88
         </a>
         ]. Patients treated with aztreonam three times daily had greater improvements in FEV
         <sub>
          1
         </sub>
         and better patient-reported respiratory symptom scores than those receiving aztreonam twice daily. A separate randomized study showed that the benefit of inhaled aztreonam was greatest in patients with more severe lung disease (FEV
         <sub>
          1
         </sub>
         &lt;90 percent predicted) compared with those with milder lung disease (FEV
         <sub>
          1
         </sub>
         ≥90 percent predicted) [
         <a href="#rid89">
          89
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H18">
         <span class="h3">
          Inhaled colistin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inhaled
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         (colistimethate sodium) is used to treat chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection in CF. In the United States, it is delivered by nebulizing an intravenous formulation (an off-label use). Outside of the United States, formulations designed for inhalation are available, either as a powder intended for suspension in liquid and nebulization, or as capsules containing a dry powder that is directly inhaled. Potential adverse effects include bronchospasm, particularly among patients with a history of wheezing, atopy, or asthma [
         <a href="#rid90">
          90
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/486.html" rel="external">
          "Polymyxins: An overview", section on 'Inhaled administration'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          Colistin
         </a>
         is a polypeptide antibiotic with antipseudomonal activity, which is preserved against many multidrug-resistant strains, including aminoglycoside-resistant strains. Unlike when administered intravenously, inhaled colistin does not appear to have significant renal toxicity and neurotoxicity. The dose is 150 mg, typically diluted in 2 mL of sterile water and administered by nebulizer twice per day for 28 days, alternating with 28 days off treatment.
        </p>
        <p>
         There are few data comparing nebulized
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         to placebo. A randomized, blinded, placebo-controlled trial of 40 subjects received twice-daily colistin compared with placebo for three months [
         <a href="#rid91">
          91
         </a>
         ]. Eleven subjects did not complete the study. A score reflecting symptoms was significantly better in the colistin group, but FEV
         <sub>
          1
         </sub>
         was not significantly different. Better evidence exists evaluating the dry powder formulation: In a phase 3 trial, 380 subjects were randomized to twice-daily inhaled colistin for 24 weeks without interruption versus twice-daily
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         that was cycled on and off every four weeks [
         <a href="#rid92">
          92
         </a>
         ]. There was no difference in FEV
         <sub>
          1
         </sub>
         , the primary endpoint. These results led to regulatory approval of the dry powder formulation in the European Union. Inhaled colistin is being studied in combination with other antibiotics for various clinical situations.
        </p>
        <p class="headingAnchor" id="H518504261">
         <span class="h3">
          Comparison of different inhaled antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         Few studies have compared the effectiveness of different inhaled antibiotics, so firm conclusions cannot be made.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobramycin
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          colistin
         </strong>
         – Two randomized trials comparing inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         with
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         in patients with chronic
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection yielded conflicting results. In one trial, treatment with inhaled tobramycin for one month improved lung function (FEV
         <sub>
          1
         </sub>
         percent predicted), whereas inhaled colistin did not [
         <a href="#rid93">
          93
         </a>
         ]. An open-label five-month extension showed persistence of the superiority of tobramycin over colistin [
         <a href="#rid94">
          94
         </a>
         ]. Contrasting results were found in a different trial of 380 subjects who were treated with three 28-day cycles of inhaled nebulized tobramycin or a powered preparation of colistimethate over a total of 24 weeks [
         <a href="#rid92">
          92
         </a>
         ]. Colistin was found to be noninferior to tobramycin for the primary endpoint, which was change in mean FEV
         <sub>
          1
         </sub>
         percent predicted from baseline to week 24. Additional clinical trials will be needed to resolve whether there is an efficacy difference between tobramycin and colistimethate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Tobramycin
         </strong>
         <strong>
          versus
         </strong>
         <strong>
          aztreonam
         </strong>
         – One randomized trial in 268 patients suggested an advantage of switching from inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         to
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         . After three 28-day cycles of treatment, the group treated with aztreonam had mean FEV
         <sub>
          1
         </sub>
         percent predicted that was 7.8 percent higher than the tobramycin group (95% CI 3.86-11.73, p&lt;0.001) [
         <a href="#rid95">
          95
         </a>
         ]. A potentially confounding factor is that during the year prior to enrollment, 85 percent of the patients enrolled in this study had been treated with inhaled tobramycin and some had been treated with colistimethate. Apparently none had received aztreonam. Therefore, this study reflects primarily the effects of switching from tobramycin to aztreonam, rather than the effect of each treatment in previously untreated patients. Unfortunately, there are no studies comparing tobramycin with aztreonam in patients who are naïve to both drugs or who have been receiving chronic aztreonam but not tobramycin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Colistin
         </strong>
         <strong>
          versus other inhaled antibiotics
         </strong>
         – A United Kingdom CF registry study found no difference in safety indicators of patients prescribed dry powder
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         with those receiving any other inhaled antibiotics [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H51125702">
         <span class="h2">
          Oral azithromycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          Azithromycin
         </a>
         is a macrolide antibiotic that has been shown in randomized trials to have clinical benefit including for those with chronic
         <em>
          P. aeruginosa
         </em>
         infection, despite the fact that
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is routinely resistant to it when tested by standard methodology in clinical microbiology laboratories. Possible explanations for its beneficial effects are that it has antiinflammatory properties or that it alters the
         <em>
          Pseudomonas
         </em>
         phenotype without inhibiting bacterial growth. Because the benefits of azithromycin do not appear to be due to direct antimicrobial effects, its use is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         .)
        </p>
        <p>
         Of note, concern has been raised that chronic use of oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         may reduce the efficacy of inhaled or intravenous
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         . Retrospective analyses of data collected in trials of inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         and tobramycin found that patients receiving oral azithromycin showed less improvement in FEV
         <sub>
          1
         </sub>
         from inhaled tobramycin compared with inhaled aztreonam [
         <a href="#rid96">
          96,97
         </a>
         ]. However, a prospective clinical trial of azithromycin versus placebo on relative change from baseline in FEV
         <sub>
          1
         </sub>
         following four weeks of inhaled tobramycin found no significant effect from azithromycin (
         <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.clinicaltrials.gov%2Fstudy%2FNCT02677701&amp;token=Rti1NBSWdX%2F%2FH%2FlCKGrzlGu03gYcMJXuTK3xOgZRWSwlC1HsqQESslEH7afkkt6jpqQLKwt1yvGaHvqimK2taw%3D%3D&amp;TOPIC_ID=6371" target="_blank">
          NCT02677701
         </a>
         ) (see
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         ). In contrast, an antagonistic effect of azithromycin has been reported for intravenous tobramycin used to treat pulmonary exacerbations. (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Managing the chronically prescribed antibiotics'
         </a>
         .)
        </p>
        <p>
         There is no consensus within the CF community on how to respond to this provocative but as yet inconclusive information [
         <a href="#rid98">
          98
         </a>
         ]. Options include avoiding chronic
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         for patients who are likely to be prescribed
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         in the near future, prescribing azithromycin but selecting antibiotics other than tobramycin to treat pulmonary exacerbations, or continuing the current practice of prescribing both azithromycin and tobramycin while waiting for more definitive data.
        </p>
        <p class="headingAnchor" id="H4138893105">
         <span class="h2">
          Practices that are not recommended
         </span>
         <span class="headingEndMark">
          —
         </span>
         The following interventions have been advocated to control the progression of pulmonary disease. We do not recommend their use, due to lack of evidence for benefit and potential risks including induction of antibiotic resistance.
        </p>
        <p class="headingAnchor" id="H2758923612">
         <span class="h3">
          Other oral antibiotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         We suggest not prescribing chronic or intermittent oral antibiotics other than
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         , because their uncertain benefits do not outweigh the problems caused by induction of antibiotic resistance and side effects. Despite the lack of experimental evidence, it is the practice of some clinicians to administer oral antibiotics chronically, particularly when sputum cultures demonstrate bacteria that are sensitive to such drugs. However, chronic use of antibiotics frequently induces antibiotic resistance, which does not necessarily abate when antibiotic treatment is stopped [
         <a href="#rid99">
          99
         </a>
         ]. This is particularly true for fluoroquinolones, which have a high propensity to induce both reversible and permanent resistance in
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         .
        </p>
        <p>
         Intermittent courses of prophylactic antibiotics have been advocated as a means of conferring benefit with less risk of subsequent resistance. However, there are few clinical data documenting the effectiveness of such an approach. One study of oral
         <a class="drug drug_general" data-topicid="9267" href="/z/d/drug information/9267.html" rel="external">
          ciprofloxacin
         </a>
         administered for 10 days every three months for one year in a small number of patients failed to show benefits in terms of FEV
         <sub>
          1
         </sub>
         , the number of hospitalizations, or the requirement for intravenous antibiotics [
         <a href="#rid100">
          100
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2273043731">
         <span class="h3">
          Periodic hospitalizations
         </span>
         <span class="headingEndMark">
          —
         </span>
         We advise against regularly planned hospitalizations for preventive therapy, which may include intravenous antibiotics and intensified airway clearance therapies (referred to as "clean outs") [
         <a href="#rid101">
          101
         </a>
         ]. This practice was frequently used in the past but has been generally abandoned in North America and many other settings due to lack of proof of benefit, high cost of treatment, and disruption of patients' daily lives. Furthermore, there is the continuing concern that frequent use of intravenous antibiotics will prematurely select multidrug-resistant organisms, making treatment of inevitable acute exacerbations more difficult.
        </p>
        <p>
         The practice of periodic hospitalization for clean out was pioneered by clinicians in the Danish Cystic Fibrosis Center in Copenhagen [
         <a href="#rid102">
          102
         </a>
         ]. Patients chronically infected with
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         were admitted to a hospital for two weeks every three to four months to receive intravenous and inhaled antibiotics. After this practice was initiated, there was an improvement in survival compared with a historical control population from the same institution. However, the lack of a concurrent, randomized control population makes it difficult to determine whether the periodic hospitalizations are responsible for the improvement.
        </p>
        <p>
         Only a few randomized trials have examined periodic elective hospitalization, and these have failed to show benefit compared with hospitalization of patients only when they are clinically worsening [
         <a href="#rid103">
          103-105
         </a>
         ]. A trial of 19 subjects with modestly elevated titer of anti-
         <em>
          Pseudomonas
         </em>
         immunoglobulin G (IgG; implying recent infection) were sequentially assigned to usual care or to be hospitalized with intravenous antipseudomonal antibiotics every four months. After one year, FEV
         <sub>
          1
         </sub>
         did not differ between groups [
         <a href="#rid105">
          105
         </a>
         ]. A larger prospective trial randomly assigned 60 patients to receive either regular antipseudomonal antibiotics every three months (clean out) or antibiotics only when indicated by clinical deterioration (symptomatically treated) [
         <a href="#rid104">
          104
         </a>
         ]. After three years of follow-up, no significant differences in spirometry or survival were noted between the two groups. Of note, the number of days of intravenous antibiotics in the clean out group was only slightly higher (1.2 to 1.5 times) than the symptomatically treated group. In the earlier Danish report, patients treated with periodic hospitalization for clean out received approximately 1.9 times the amount of intravenous antibiotics as compared with their historical controls [
         <a href="#rid102">
          102
         </a>
         ]. Some authors have suggested that the United Kingdom study did not adequately test the role of scheduled therapy, because the intensity of antibiotic therapy in the symptomatically treated group was relatively high [
         <a href="#rid106">
          106
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4202024">
         <span class="h1">
          OTHER SPECIFIC PATHOGENS
         </span>
        </p>
        <p class="headingAnchor" id="H3733026178">
         <span class="h2">
          <i>
           Aspergillus
          </i>
          species
         </span>
         <span class="headingEndMark">
          —
         </span>
         Cultures of sputum from patients with CF often yield
         <em>
          Aspergillus
         </em>
         species, but there is insufficient evidence to recommend treatment solely on its presence [
         <a href="#rid107">
          107
         </a>
         ]. We do consider treatment when criteria are met for allergic bronchopulmonary aspergillosis [
         <a href="#rid108">
          108-110
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2419.html" rel="external">
          "Clinical manifestations and diagnosis of allergic bronchopulmonary aspergillosis", section on 'Diagnosis of ABPA in cystic fibrosis'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/104431.html" rel="external">
          "Treatment of allergic bronchopulmonary aspergillosis"
         </a>
         ). The practice of using azoles varies among lung transplant centers for patients with
         <em>
          Aspergillus
         </em>
         in respiratory secretions, with some using them pre-transplant and many post-transplant [
         <a href="#rid111">
          111
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1408.html" rel="external">
          "Prophylaxis of infections in solid organ transplantation"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1394.html" rel="external">
          "Fungal infections following lung transplantation"
         </a>
         .)
        </p>
        <p>
         Results of observational studies are conflicting regarding the consequences of detecting
         <em>
          Aspergillus
         </em>
         in respiratory secretions, with several studies suggesting no association between the presence of
         <em>
          Aspergillus
         </em>
         and the clinical course in patients without allergic symptoms [
         <a href="#rid112">
          112-115
         </a>
         ], while another study did find this association [
         <a href="#rid116">
          116
         </a>
         ]. However, it is not clear whether this association is causal or whether
         <em>
          Aspergillus
         </em>
         is merely a marker of more severe lung disease.
        </p>
        <p>
         Studies have generally failed to show a benefit of treating
         <em>
          Aspergillus
         </em>
         in patients without allergic symptoms. A small trial randomized subjects with persistently positive
         <em>
          Aspergillus
         </em>
         cultures to 24 weeks of
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         therapy versus placebo [
         <a href="#rid117">
          117
         </a>
         ]. No statistically significant improvement in time to next pulmonary exacerbation or in forced expiratory volume in one second (FEV
         <sub>
          1
         </sub>
         ) were noted with itraconazole treatment, but the study was limited by the small number of participants and the observation that 43 percent of the subjects treated with itraconazole did not achieve what was considered to be therapeutic blood levels. No randomized trials have been performed testing efficacy of
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         or
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         in CF patients. However, the better bioavailability of voriconazole has led many clinicians to use it in place of itraconazole [
         <a href="#rid118">
          118
         </a>
         ]. Regardless, drug level monitoring is recommended for itraconazole, voriconazole, and posaconazole due to patient-to-patient variation in drug absorption and metabolism. (See
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         .)
        </p>
        <p>
         Of note,
         <a class="drug drug_general" data-topicid="8586" href="/z/d/drug information/8586.html" rel="external">
          itraconazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">
          voriconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">
          posaconazole
         </a>
         are strong inhibitors of cytochrome P450 3A4, the predominant enzyme that metabolizes elexacaftor, tezacaftor, and
         <a class="drug drug_general" data-topicid="17144" href="/z/d/drug information/17144.html" rel="external">
          ivacaftor
         </a>
         (see
         <a class="medical medical_review" href="/z/d/html/495.html" rel="external">
          "Pharmacology of azoles"
         </a>
         ). Dose reduction of these CF transmembrane conductance regulator (CFTR) modulators is required when co-administered with these antifungal agents. These azoles can induce liver injury, and voriconazole is associated with vision changes and photosensitivity reactions. (See
         <a class="drug drug_general" href="/z/d/drug information/17144.html" rel="external">
          "Ivacaftor: Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/116733.html" rel="external">
          "Tezacaftor and ivacaftor: Drug information"
         </a>
         and
         <a class="drug drug_general" href="/z/d/drug information/122968.html" rel="external">
          "Elexacaftor, tezacaftor, and ivacaftor co-packaged with ivacaftor: Drug information"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H23">
         <span class="h2">
          Nontuberculous mycobacteria
         </span>
         <span class="headingEndMark">
          —
         </span>
         Nontuberculous mycobacteria (NTM) can be isolated from the sputum in 10 to 20 percent of individuals with CF, including
         <em>
          M
         </em>
         .
         <em>
          avium
         </em>
         complex and
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         complex (see
         <a class="local">
          'Nontuberculous mycobacteria'
         </a>
         above). Those with sputum samples that are smear-positive for acid-fast bacilli (AFB) are likely to have a higher burden of bacteria than those who are smear-negative. The clinical implications of detecting NTM in sputum samples of patients with CF are variable, but in some cases, the infection is associated with declining pulmonary status and warrants treatment.
        </p>
        <p>
         Progressive inflammatory lung damage, known as NTM pulmonary disease, occurs in a subset of patients with NTM, causing increased cough, sputum production, shortness of breath, and deteriorating pulmonary function tests. Fever, night sweats, and weight loss are uncommon in CF patients with NTM disease, but if these features are present, they support this diagnosis. It is estimated that between 20 to 59 percent of CF patients with positive NTM cultures meet diagnostic criteria for NTM pulmonary disease [
         <a href="#rid119">
          119
         </a>
         ]. Although radiographic features of NTM pulmonary disease overlap with those seen in the general CF population, high-resolution computed tomography (HRCT) findings that suggest concomitant NTM lung disease are prominent nodular infiltrates, tree-in-bud opacities in lung regions having minimal bronchiectasis, and parenchymal cavities.
        </p>
        <p>
         Identifying CF patients who might have NTM pulmonary disease is best done by routine screening for all CF patients and by early evaluation of the subgroup of patients who have signs and symptoms suggesting NTM pulmonary disease. An expert panel convened jointly by the Cystic Fibrosis Foundation (CFF) and the European Cystic Fibrosis Society (ECFS) has published a comprehensive set of recommendations for the screening, diagnosis, and management of NTM in CF, with which we concur [
         <a href="#rid24">
          24
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Screening
         </strong>
         – To detect NTM in patients with CF, we recommend that all expectorating patients have their sputum screened annually by examining smears stained for AFB and culture. Oropharyngeal swabs are not recommended. The recommendations by the CFF/ECFS panel regarding collection and processing of the samples should be followed [
         <a href="#rid24">
          24
         </a>
         ]. If NTM are isolated, they should be further identified using molecular techniques. Patients screening positive and those with a clinical suspicion of NTM pulmonary disease suggested by worsening pulmonary symptoms or accelerated decline in FEV
         <sub>
          1
         </sub>
         should be further evaluated to determine if they fulfill diagnostic criteria for NTM lung disease, as detailed below.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Importantly, for any patient taking chronic
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         who screens positive for NTM or who is suspected of being infected with NTM, the azithromycin should be temporarily halted pending further diagnostic evaluation to reduce the risk that monotherapy will induce resistance of the NTM to azithromycin. A single-center retrospective study reported that initial isolates of mycobacterium avium complex in CF patients receiving chronic azithromycin therapy are unlikely to be macrolide resistant [
         <a href="#rid120">
          120
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Diagnosis
         </strong>
         – Diagnostic criteria for NTM pulmonary disease in CF patients are the same as for the general population, as initially outlined by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA) [
         <a href="#rid32">
          32
         </a>
         ] and endorsed by the CFF/ECFS expert panel [
         <a href="#rid24">
          24
         </a>
         ]. These criteria require symptoms suggesting active NTM disease, imaging studies (HRCT) consistent with NTM pulmonary disease, and microbiologic identification of NTM  (
         <a class="graphic graphic_table graphicRef61404" href="/z/d/graphic/61404.html" rel="external">
          table 2
         </a>
         ) [
         <a href="#rid32">
          32
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/5342.html" rel="external">
          "Overview of nontuberculous mycobacterial infections", section on 'Diagnostic criteria'
         </a>
         ). Other pathogens and comorbidities should be considered as potential contributors to the patient's symptoms and radiologic findings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         When clinical features suggest NTM pulmonary disease, the patient should have respiratory secretions tested for NTM and an HRCT performed  (
         <a class="graphic graphic_algorithm graphicRef106965" href="/z/d/graphic/106965.html" rel="external">
          algorithm 1
         </a>
         ) [
         <a href="#rid24">
          24
         </a>
         ]. The microbiologic evaluation follows a stepwise approach, starting with examination of expectorated or induced sputum. If the results of sputum testing are negative and imaging is suspicious for NTM pulmonary disease, bronchoscopy should be performed, with bronchial washing or bronchoalveolar lavage targeted to lung regions appearing suspicious for NTM disease on HRCT. The microbiologic criteria for diagnosis of NTM pulmonary disease require isolation of NTM from sputum on two occasions or from bronchial wash/alveolar lavage on one occasion [
         <a href="#rid32">
          32
         </a>
         ]. Transbronchial lung biopsies should not be performed routinely, because the risks of complications including pneumothorax and hemoptysis likely exceed the diagnostic benefit.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Those patients with NTM detected during annual sputum screening should be scrutinized carefully for evidence of active NTM pulmonary disease. Additional sputum samples should be examined by AFB staining and culture. Those with suspicious symptoms, worsening pulmonary function test results, or repeatedly positive AFB cultures should have an HRCT performed. The diagnosis of NTM pulmonary disease should be made if the accumulated data fulfill the ATS/IDSA criteria.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Treatment
         </strong>
         – If the diagnostic criteria for NTM pulmonary disease are fulfilled, treatment for NTM should be seriously considered. However, prior to initiating treatment, it is appropriate to provide a course of intensified treatment targeting the bacteria other than NTM that infect the patient's airways (see
         <a class="medical medical_review" href="/z/d/html/110933.html" rel="external">
          "Cystic fibrosis: Management of pulmonary exacerbations"
         </a>
         ). If such treatment returns the patient to a baseline level of symptoms and lung function, NTM treatment may be deferred but with close follow-up. Unfortunately, eradication of NTM from airway secretions of CF patients is difficult to achieve, particularly in those infected with
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         , and drug toxicities are frequent [
         <a href="#rid31">
          31,121,122
         </a>
         ]. The decision to initiate NTM therapy needs to be individualized for each patient based on assessment of risks and benefits and consultation with infectious diseases specialists with CF experience. Some patients may be better served if left untreated [
         <a href="#rid123">
          123
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         If the decision is made to treat NTM pulmonary disease in a patient with CF, the approach to treatment is similar to that for patients without CF, except that daily rather than intermittent antibiotic therapy is preferred [
         <a href="#rid24">
          24
         </a>
         ]. Other details of treatment in patients without CF are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Transplant considerations
         </strong>
         – Infection with
         <em>
          M
         </em>
         .
         <em>
          avium
         </em>
         complex appears to have no adverse impact on patients with CF who undergo lung transplantation [
         <a href="#rid124">
          124-126
         </a>
         ]. However,
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         complex infection can complicate lung transplantation, causing soft tissue and mediastinal abscesses that can recur despite treatment with surgical drainage and antibiotics. The CFF/ECFS guidelines recommend that assessment for NTM pulmonary disease be included in any lung transplant evaluation and that NTM be treated prior to transplant if detected [
         <a href="#rid24">
          24
         </a>
         ]. Current or previous positive cultures for NTM should not preclude consideration for transplant, and patients with evidence of eradication or sequential negative cultures during treatment may be eligible for transplant listing, although there are significant variations in policy among centers [
         <a href="#rid126">
          126
         </a>
         ]. Persistent
         <em>
          M
         </em>
         .
         <em>
          avium
         </em>
         complex or
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         complex infection despite optimal treatment is not an absolute contraindication for transplantation. Referral of candidates to centers having special expertise in transplanting patients with these organisms should be considered.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H25">
         <span class="h1">
          INFECTION PREVENTION AND CONTROL
         </span>
         <span class="headingEndMark">
          —
         </span>
         Evidence is accumulating that a variety of respiratory pathogens can be transmitted among individuals with CF within the health care system, despite implementation of infection control guidelines similar to those that were published in 2003 by the Cystic Fibrosis Foundation (CFF). In particular, highly transmissible strains of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         have been reported in Europe, Canada, and Australia [
         <a href="#rid127">
          127,128
         </a>
         ], and infection with these strains is associated with increased health care needs and antibiotic use as compared with infection with sporadic strains [
         <a href="#rid10">
          10,129
         </a>
         ] (see
         <a class="local">
          'Pseudomonas aeruginosa'
         </a>
         above). Spread of
         <em>
          Burkholderia
         </em>
         species, methicillin-resistant
         <em>
          S
         </em>
         .
         <em>
          aureus
         </em>
         (MRSA), and multidrug-resistant
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         between CF patients has been detected in individual CF centers [
         <a href="#rid29">
          29,33,130,131
         </a>
         ]. Less commonly, strains of
         <em>
          S
         </em>
         .
         <em>
          maltophilia
         </em>
         ,
         <em>
          Achromobacter
         </em>
         species, and other Gram-negative pathogens may be shared by individuals with CF.
        </p>
        <p>
         The possibility of transmission of
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         between patients was explored in a study that employed whole-genome analysis of 1080 clinical isolates of
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         from 517 CF patients attending centers in Europe, the United States, and Australia [
         <a href="#rid29">
          29
         </a>
         ]. Isolates obtained from these widely scattered sites were found to have near-identical sequences. These findings led the authors to suggest worldwide person-to-person transmission of
         <em>
          M
         </em>
         .
         <em>
          abscessus
         </em>
         clones between CF patients. However, the study did not exclude another likely explanation for their findings, which is that the clones are distributed globally in the environment and that patients become infected from them locally without direct patient-to-patient transmission. Following publication of this article, the CFF has made no new recommendations beyond the existing guidelines, which are designed to limit spread of all infectious agents between CF patients.
        </p>
        <p>
         To minimize risk of transmission, the CFF has published updated guidelines for infection prevention and control to be applied to all individuals with CF, regardless of respiratory tract culture results [
         <a href="#rid130">
          130
         </a>
         ]. Although few of the guidelines have been tested to determine their independent effectiveness in limiting transfer of microorganisms, implementation of sets of enhanced guidelines has been successful at terminating transmission at individual CF centers experiencing spread of specific bacteria. The new guidelines include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contact precautions – Clinicians should always use contact precautions (ie, gown and gloves) when caring for individuals with CF in ambulatory and inpatient settings.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Spacing of patients – Individuals with CF should be separated from each other by at least six feet in all settings to reduce the risk of droplet transmission of CF pathogens. This includes measures so that patients do not spend time in a waiting room or common area. Inpatients with CF should be housed in a single-patient hospital room.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Hand hygiene – All individuals with CF, family members, and friends should perform hand hygiene where there is potential for contamination of hands with pathogens (eg, entering and exiting CF clinic, examination room, or hospital room or after performing chest physiotherapy).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Masks – All individuals with CF should routinely wear a surgical mask when in a health care setting [
         <a href="#rid132">
          132
         </a>
         ]. Reusable cloth masks that some patients obtain commercially provide inadequate protection and are not recommended for use in health care settings.
        </p>
        <p>
        </p>
        <p>
         In addition, the guideline includes specific measures for pulmonary function testing and sterilization of hospital equipment [
         <a href="#rid130">
          130
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H26">
         <span class="h1">
          PREVENTIVE CARE
         </span>
         <span class="headingEndMark">
          —
         </span>
         Inflammation induced by viral upper respiratory tract infections appears to initiate exacerbations of CF lung disease. For all infants with CF, immunoprophylaxis with
         <a class="drug drug_general" data-topicid="141488" href="/z/d/drug information/141488.html" rel="external">
          nirsevimab
         </a>
         is recommended during the first respiratory syncytial virus (RSV) season (similar to all infants), and selected infants should also receive nirsevimab during the second RSV season. Annual immunization against influenza is also recommended for all people with CF beginning at six months of age, unless they have strong contraindications to receiving the vaccine. Although people with CF become infected with
         <em>
          Streptococcus
         </em>
         <em>
          pneumoniae
         </em>
         only rarely, the availability and safety of the vaccine make its use advisable in this population. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Prevention of infection'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15389.html" rel="external">
          "Respiratory syncytial virus infection: Prevention in infants and children", section on 'Immunoprophylaxis'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3791916788">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109226.html" rel="external">
          "Society guideline links: Cystic fibrosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H11004603">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topic (see
         <a class="medical medical_basics" href="/z/d/html/16906.html" rel="external">
          "Patient education: Cystic fibrosis (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H27">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Common pathogens
         </strong>
         – Cystic fibrosis (CF) lung disease is characterized by persistent bacterial infection.
         <em>
          Staphylococcus
         </em>
         <em>
          aureus
         </em>
         and
         <em>
          Pseudomonas
         </em>
         <em>
          aeruginosa
         </em>
         are the most prevalent pathogens  (
         <a class="graphic graphic_figure graphicRef74073" href="/z/d/graphic/74073.html" rel="external">
          figure 2
         </a>
         and
         <a class="graphic graphic_table graphicRef55018" href="/z/d/graphic/55018.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pathogens'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Sputum cultures
         </strong>
         – Cultures of expectorated sputum or throat swabs should be performed at least every three months during routine clinic visits.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         When
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         is first detected, we recommend prompt treatment using an early eradication protocol, rather than delayed or no treatment (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). We suggest using inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         alone (300 mg in 5 mL, administered twice daily) for 28 days, rather than a regimen including other antibiotics (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). The therapy is repeated only if surveillance cultures show recurrence of
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         . (See
         <a class="local">
          'Prevention and eradication'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         The results of sputum cultures are used to guide selection of antibiotics in the event of an acute exacerbation. (See
         <a class="local">
          'Periodic surveillance cultures'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          <em>
           Pseudomonas
          </em>
         </strong>
         <strong>
          infection –
         </strong>
         For patients with persistent
         <em>
          P
         </em>
         .
         <em>
          aeruginosa
         </em>
         infection, we recommend chronic treatment with inhaled
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         , rather than no inhaled antibiotic (
         <a class="grade" href="https:///uptodate/show/grade_2" rel="external">
          Grade 1B
         </a>
         ). Inhaled
         <a class="drug drug_general" data-topicid="9047" href="/z/d/drug information/9047.html" rel="external">
          aztreonam
         </a>
         lysine is a reasonable alternative, as is inhaled
         <a class="drug drug_general" data-topicid="8718" href="/z/d/drug information/8718.html" rel="external">
          colistin
         </a>
         . The inhaled antibiotic is typically cycled between 28 days on and 28 days off treatment. For patients with deteriorating pulmonary status and/or recurrent pulmonary exacerbations despite cyclic treatment with a single inhaled antibiotic, it is becoming common practice to administer inhaled antibiotics continuously, by alternating 28 days of one antibiotic with 28 days of another. (See
         <a class="local">
          'Inhaled antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Not recommended
         </strong>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Chronic oral antibiotics
         </strong>
         – We suggest
         <strong>
          against
         </strong>
         prescribing chronic or intermittent oral antibiotic therapy other than oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Evidence of benefit is lacking, and there is concern about promoting antibiotic resistance with this therapy. (See
         <a class="local">
          'Other oral antibiotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         Indications for chronic treatment with oral
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6372.html" rel="external">
          "Cystic fibrosis: Overview of the treatment of lung disease", section on 'Azithromycin'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Periodic hospitalizations
         </strong>
         – In addition, we suggest
         <strong>
          against
         </strong>
         performing regularly scheduled elective hospitalizations for antibiotics and intensified chest physiotherapy ("clean outs") (
         <a class="grade" href="https:///uptodate/show/grade_6" rel="external">
          Grade 2C
         </a>
         ). Limited clinical trial data suggest that this treatment approach is not more effective than hospitalization only for acute pulmonary exacerbations. (See
         <a class="local">
          'Periodic hospitalizations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Nontuberculous mycobacteria (NTM)
         </strong>
         – NTM are increasingly identified in patients with CF. The clinical implications of detecting NTM in sputum samples of patients with CF are variable, but in some cases, the infection is associated with declining pulmonary function and warrants treatment. All expectorating patients should have annual screening for NTM in sputum. Those testing positive and patients with a clinical suspicion of NTM pulmonary disease suggested by unexplained worsening of symptoms or pulmonary function test results should be further evaluated. For any patient taking chronic
         <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">
          azithromycin
         </a>
         who screen positive for NTM or who is suspected of being infected with NTM, azithromycin should be temporarily held pending further evaluation to reduce the risk that monotherapy will induce resistance of the NTM to azithromycin. (See
         <a class="local">
          'Nontuberculous mycobacteria'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Infection control
         </strong>
         – To reduce transmission of pathogens, the Cystic Fibrosis Foundation (CFF) recommends the following measures for all CF patients, regardless of a patient's respiratory tract culture results (see
         <a class="local">
          'Infection prevention and control'
         </a>
         above):
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Clinicians use contact precautions (gown and surgical masks) at all times
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients wear surgical masks in the health care setting
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Patients with CF should not congregate within or outside of the health care setting and should be separated by at least six feet, and inpatients with CF should be housed in single-patient rooms
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Rommens JM, Iannuzzi MC, Kerem B, et al. Identification of the cystic fibrosis gene: chromosome walking and jumping. Science 1989; 245:1059.
          </a>
         </li>
         <li class="breakAll">
          Cystic Fibrosis Foundation. 2019 Patient Registry: Annual Data Report. 2020. Available at: https://www.cff.org/Research/Researcher-Resources/Patient-Registry/2019-Patient-Registry-Annual-Data-Report.pdf (Accessed on July 19, 2021).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zemanick ET, Hoffman LR. Cystic Fibrosis: Microbiology and Host Response. Pediatr Clin North Am 2016; 63:617.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kopp BT, Nicholson L, Paul G, et al. Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry. Pediatr Pulmonol 2015; 50:754.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Crull MR, Somayaji R, Ramos KJ, et al. Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study. Clin Infect Dis 2018; 67:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsay KA, Sandhu H, Geake JB, et al. The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis. J Cyst Fibros 2017; 16:70.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salsgiver EL, Fink AK, Knapp EA, et al. Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis. Chest 2016; 149:390.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld M, Gibson RL, McNamara S, et al. Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis. Pediatr Pulmonol 2001; 32:356.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Emerson J, Rosenfeld M, McNamara S, et al. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol 2002; 34:91.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaron SD, Vandemheen KL, Ramotar K, et al. Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis. JAMA 2010; 304:2145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somayaji R, Lam JC, Surette MG, et al. Long-term clinical outcomes of 'Prairie Epidemic Strain' Pseudomonas aeruginosa infection in adults with cystic fibrosis. Thorax 2017; 72:333.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sagel SD, Gibson RL, Emerson J, et al. Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis. J Pediatr 2009; 154:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasenbrook EC, Merlo CA, Diener-West M, et al. Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:814.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawicki GS, Rasouliyan L, Pasta DJ, et al. The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis. Pediatr Pulmonol 2008; 43:1117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasenbrook EC, Checkley W, Merlo CA, et al. Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis. JAMA 2010; 303:2386.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vandamme P, Dawyndt P. Classification and identification of the Burkholderia cepacia complex: Past, present and future. Syst Appl Microbiol 2011; 34:87.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kenna DTD, Lilley D, Coward A, et al. Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients. J Med Microbiol 2017; 66:490.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones AM, Dodd ME, Govan JR, et al. Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis. Thorax 2004; 59:948.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Somayaji R, Yau YCW, Tullis E, et al. Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis. Ann Am Thorac Soc 2020; 17:1542.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray S, Charbeneau J, Marshall BC, LiPuma JJ. Impact of burkholderia infection on lung transplantation in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:363.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stephenson AL, Sykes J, Berthiaume Y, et al. Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis. J Heart Lung Transplant 2015; 34:1139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weill D. Lung transplantation: indications and contraindications. J Thorac Dis 2018; 10:4574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjemian J, Olivier KN, Prevots DR. Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk. Am J Respir Crit Care Med 2014; 190:581.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Floto RA, Olivier KN, Saiman L, et al. US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis. Thorax 2016; 71 Suppl 1:i1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adjemian J, Olivier KN, Prevots DR. Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014. Ann Am Thorac Soc 2018; 15:817.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003; 167:828.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mussaffi H, Rivlin J, Shalit I, et al. Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy. Eur Respir J 2005; 25:324.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Esther CR Jr, Esserman DA, Gilligan P, et al. Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis. J Cyst Fibros 2010; 9:117.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant JM, Grogono DM, Rodriguez-Rincon D, et al. Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science 2016; 354:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shaw LP, Doyle RM, Kavaliunaite E, et al. Children With Cystic Fibrosis Are Infected With Multiple Subpopulations of Mycobacterium abscessus With Different Antimicrobial Resistance Profiles. Clin Infect Dis 2019; 69:1678.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rollet-Cohen V, Roux AL, Le Bourgeois M, et al. Mycobacterium bolletii Lung Disease in Cystic Fibrosis. Chest 2019; 156:247.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007; 175:367.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lipuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010; 23:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caverly LJ, LiPuma JJ. Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice. Expert Rev Respir Med 2018; 12:857.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JK, De Groote MA, Sagel SD, et al. Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis. Proc Natl Acad Sci U S A 2007; 104:20529.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med 2008; 177:995.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Carmody LA, Caverly LJ, Foster BK, et al. Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis. PLoS One 2018; 13:e0194060.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saiman L, Siegel J, Cystic Fibrosis Foundation Consensus Conference on Infection Control Participants. Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission. Am J Infect Control 2003; 31:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cystic Fibrosis Foundation, Borowitz D, Robinson KA, et al. Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis. J Pediatr 2009; 155:S73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lahiri T, Hempstead SE, Brady C, et al. Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis. Pediatrics 2016; 137.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Heltshe SL, Mayer-Hamblett N, Burns JL, et al. Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor. Clin Infect Dis 2015; 60:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frost FJ, Nazareth DS, Charman SC, et al. Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data. Ann Am Thorac Soc 2019; 16:1375.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harris JK, Wagner BD, Zemanick ET, et al. Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation. Ann Am Thorac Soc 2020; 17:212.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013; 187:680.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tramper-Stranders GA, Wolfs TF, van Haren Noman S, et al. Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Thorax 2010; 65:915.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosenfeld M, Rayner O, Smyth AR. Prophylactic anti-staphylococcal antibiotics for cystic fibrosis. Cochrane Database Syst Rev 2020; 9:CD001912.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stutman HR, Lieberman JM, Nussbaum E, Marks MI. Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial. J Pediatr 2002; 140:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hurley MN, Fogarty A, McKeever TM, et al. Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis. Ann Am Thorac Soc 2018; 15:42.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treggiari MM, Rosenfeld M, Retsch-Bogart G, et al. Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis. Pediatr Pulmonol 2007; 42:751.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection. Ann Am Thorac Soc 2014; 11:1640.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med 2011; 165:847.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Langton Hewer SC, Smith S, Rowbotham NJ, et al. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev 2023; 6:CD004197.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratjen F, Munck A, Kho P, et al. Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial. Thorax 2010; 65:286.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols. Thorax 2012; 67:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer-Hamblett N, Kloster M, Rosenfeld M, et al. Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis. Clin Infect Dis 2015; 61:707.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ratjen F, Moeller A, McKinney ML, et al. Eradication of early P. aeruginosa infection in children &lt;7 years of age with cystic fibrosis: The early study. J Cyst Fibros 2019; 18:78.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blanchard AC, Horton E, Stanojevic S, et al. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros 2017; 16:395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tiddens HA, De Boeck K, Clancy JP, et al. Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study. J Cyst Fibros 2015; 14:111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mayer-Hamblett N, Retsch-Bogart G, Kloster M, et al. Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial. Am J Respir Crit Care Med 2018; 198:1177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hewer SCL, Smyth AR, Brown M, et al. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial. Lancet Respir Med 2020; 8:975.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kappler M, Nagel F, Feilcke M, et al. Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study. Pediatr Pulmonol 2016; 51:1010.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hall H, Gadhok R, Alshafi K, et al. Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre. Respir Med 2015; 109:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muhlebach MS, Beckett V, Popowitch E, et al. Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial. Thorax 2017; 72:318.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lo DK, Muhlebach MS, Smyth AR. Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis. Cochrane Database Syst Rev 2018; 7:CD009650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dolce D, Neri S, Grisotto L, et al. Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study. PLoS One 2019; 14:e0213497.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dezube R, Jennings MT, Rykiel M, et al. Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis. J Cyst Fibros 2019; 18:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith S, Rowbotham NJ. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. Cochrane Database Syst Rev 2022; 11:CD001021.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003; 167:841.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth AR, Bell SC, Bojcin S, et al. European Cystic Fibrosis Society Standards of Care: Best Practice guidelines. J Cyst Fibros 2014; 13 Suppl 1:S23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flume PA, Clancy JP, Retsch-Bogart GZ, et al. Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis. J Cyst Fibros 2016; 15:809.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dasenbrook EC, Konstan MW, VanDevanter DR. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. J Cyst Fibros 2015; 14:370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Van de Kerkhove C, Goeminne PC, Kicinski M, et al. Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis. J Cyst Fibros 2016; 15:802.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saiman L, Mehar F, Niu WW, et al. Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation. Clin Infect Dis 1996; 23:532.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCoy KS, Retsch-Bogart GZ, Gibson R, et al. Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis. Pediatr Pulmonol 2008; 31 Suppl:351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007; 176:957.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kimple AJ, Senior BA, Naureckas ET, et al. Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations. Int Forum Allergy Rhinol 2022; 12:1089.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkins MD, Elborn JS. Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011; 5:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. J Cyst Fibros 2011; 10:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Konstan MW, Flume PA, Galeva I, et al. One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis. Pediatr Pulmonol 2016; 51:372.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999; 340:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss RB. Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis. Chest 2002; 121:55.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Burns JL, Van Dalfsen JM, Shawar RM, et al. Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis. J Infect Dis 1999; 179:1190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bowman CM. The long-term use of inhaled tobramycin in patients with cystic fibrosis. J Cyst Fibros 2002; 1:194.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Quittner AL, Buu A. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection. Pediatr Pulmonol 2002; 33:269.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sawicki GS, Signorovitch JE, Zhang J, et al. Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution. Pediatr Pulmonol 2012; 47:44.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McCoy KS, Quittner AL, Oermann CM, et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care Med 2008; 178:921.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Retsch-Bogart GZ, Quittner AL, Gibson RL, et al. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest 2009; 135:1223.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010; 45:1121.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wainwright CE, Quittner AL, Geller DE, et al. Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa. J Cyst Fibros 2011; 10:234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alothman GA, Ho B, Alsaadi MM, et al. Bronchial constriction and inhaled colistin in cystic fibrosis. Chest 2005; 127:522.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jensen T, Pedersen SS, Garne S, et al. Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection. J Antimicrob Chemother 1987; 19:831.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schuster A, Haliburn C, Döring G, et al. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013; 68:344.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hodson ME, Gallagher CG, Govan JR. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J 2002; 20:658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros 2006; 5:261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Assael BM, Pressler T, Bilton D, et al. Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial. J Cyst Fibros 2013; 12:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nick JA, Moskowitz SM, Chmiel JF, et al. Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis. Ann Am Thorac Soc 2014; 11:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nichols DP, Happoldt CL, Bratcher PE, et al. Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis. J Cyst Fibros 2017; 16:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           VanDevanter DR, LiPuma JJ. The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis. Ann Am Thorac Soc 2019; 16:819.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Diver JM, Schollaardt T, Rabin HR, et al. Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy. Antimicrob Agents Chemother 1991; 35:1538.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sheldon CD, Assoufi BK, Hodson ME. Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa. Respir Med 1993; 87:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yankaskas JR, Marshall BC, Sufian B, et al. Cystic fibrosis adult care: consensus conference report. Chest 2004; 125:1S.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Szaff M, Høiby N, Flensborg EW. Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection. Acta Paediatr Scand 1983; 72:651.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Breen L, Aswani N. Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis. Cochrane Database Syst Rev 2012; :CD002767.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elborn JS, Prescott RJ, Stack BH, et al. Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs. Thorax 2000; 55:355.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brett MM, Simmonds EJ, Ghoneim AT, Littlewood JM. The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis. Arch Dis Child 1992; 67:1086.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Høiby N, Koch C. Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis. Thorax 2000; 55:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tracy MC, Moss RB. The myriad challenges of respiratory fungal infection in cystic fibrosis. Pediatr Pulmonol 2018; 53:S75.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Skov M, Koch C, Reimert CM, Poulsen LK. Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis. Allergy 2000; 55:50.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nikolaizik WH, Weichel M, Blaser K, Crameri R. Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy. Am J Respir Crit Care Med 2002; 165:916.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stevens DA, Moss RB, Kurup VP, et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37 Suppl 3:S225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pennington KM, Yost KJ, Escalante P, et al. Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers. Clin Transplant 2019; 33:e13630.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mroueh S, Spock A. Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis. Chest 1994; 105:32.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kraemer R, Deloséa N, Ballinari P, et al. Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis. Am J Respir Crit Care Med 2006; 174:1211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harun SN, Wainwright CE, Grimwood K, et al. Aspergillus and progression of lung disease in children with cystic fibrosis. Thorax 2019; 74:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Blomquist A, Inghammar M, Al Shakirchi M, et al. Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study. BMC Pulm Med 2022; 22:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Amin R, Dupuis A, Aaron SD, Ratjen F. The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis. Chest 2010; 137:171.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aaron SD, Vandemheen KL, Freitag A, et al. Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study. PLoS One 2012; 7:e36077.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rivosecchi RM, Samanta P, Demehin M, Nguyen MH. Pharmacokinetics of Azole Antifungals in Cystic Fibrosis. Mycopathologia 2018; 183:139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leung JM, Olivier KN. Nontuberculous mycobacteria in patients with cystic fibrosis. Semin Respir Crit Care Med 2013; 34:124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richter WJ, Nguyen JA, Wu AE, et al. Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy. J Cyst Fibros 2021; 20:555.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chacko A, Wen SCH, Hartel G, et al. Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis. Pediatr Infect Dis J 2019; 38:660.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Martiniano SL, Sontag MK, Daley CL, et al. Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis. Ann Am Thorac Soc 2014; 11:36.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Albrecht C, Ringshausen F, Ott S, et al. Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year case-control study. Eur Respir J 2016; 47:1575.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chernenko SM, Humar A, Hutcheon M, et al. Mycobacterium abscessus infections in lung transplant recipients: the international experience. J Heart Lung Transplant 2006; 25:1447.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Perez AA, Singer JP, Schwartz BS, et al. Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience. Transpl Infect Dis 2019; 21:e13084.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tissot A, Thomas MF, Corris PA, Brodlie M. NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice. BMC Pulm Med 2018; 18:86.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scott FW, Pitt TL. Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales. J Med Microbiol 2004; 53:609.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parkins MD, Glezerson BA, Sibley CD, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol 2014; 52:1127.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jones AM, Dodd ME, Morris J, et al. Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study. Chest 2010; 137:1405.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014; 35 Suppl 1:S1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bryant JM, Grogono DM, Greaves D, et al. Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study. Lancet 2013; 381:1551.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wood ME, Stockwell RE, Johnson GR, et al. Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis. Am J Respir Crit Care Med 2018; 197:348.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 6371 Version 72.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2772657" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Identification of the cystic fibrosis gene: chromosome walking and jumping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2772657" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Identification of the cystic fibrosis gene: chromosome walking and jumping.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27469179" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Cystic Fibrosis: Microbiology and Host Response.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25825016" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Geographic variations in cystic fibrosis: An analysis of the U.S. CF Foundation Registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29534149" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Changing Rates of Chronic Pseudomonas aeruginosa Infections in Cystic Fibrosis: A Population-Based Cohort Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27515017" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : The changing prevalence of pulmonary infection in adults with cystic fibrosis: A longitudinal analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26203598" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Changing Epidemiology of the Respiratory Bacteriology of Patients With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11596160" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12112774" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21081727" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27682327" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Long-term clinical outcomes of 'Prairie Epidemic Strain' Pseudomonas aeruginosa infection in adults with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18822427" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Impact of Pseudomonas and Staphylococcus infection on inflammation and clinical status in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18669817" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Persistent methicillin-resistant Staphylococcus aureus and rate of FEV1 decline in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18846559" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The impact of incident methicillin resistant Staphylococcus aureus detection on pulmonary function in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20551409" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Association between respiratory tract methicillin-resistant Staphylococcus aureus and survival in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21257278" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Classification and identification of the Burkholderia cepacia complex: Past, present and future.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28463663" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Prevalence of Burkholderia species, including members of Burkholderia cepacia complex, among UK cystic and non-cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15516469" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Burkholderia cenocepacia and Burkholderia multivorans: influence on survival in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32678679" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Clinical Outcomes Associated with Burkholderia cepacia Complex Infection in Patients with Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18535253" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Impact of burkholderia infection on lung transplantation in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26087666" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Clinical and demographic factors associated with post-lung transplantation survival in individuals with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30174910" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lung transplantation: indications and contraindications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25068291" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Nontuberculous mycobacteria among patients with cystic fibrosis in the United States: screening practices and environmental risk.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26666259" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : US Cystic Fibrosis Foundation and European Cystic Fibrosis Society consensus recommendations for the management of non-tuberculous mycobacteria in individuals with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29897781" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Epidemiology of Pulmonary Nontuberculous Mycobacterial Sputum Positivity in Patients with Cystic Fibrosis in the United States, 2010-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12433668" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15684298" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Nontuberculous mycobacteria in cystic fibrosis associated with allergic bronchopulmonary aspergillosis and steroid therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20071249" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Chronic Mycobacterium abscessus infection and lung function decline in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27846606" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30689761" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Children With Cystic Fibrosis Are Infected With Multiple Subpopulations of Mycobacterium abscessus With Different Antimicrobial Resistance Profiles.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30935892" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Mycobacterium bolletii Lung Disease in Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17277290" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20375354" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The changing microbial epidemiology in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30118374" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Cystic fibrosis respiratory microbiota: unraveling complexity to inform clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18077362" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Molecular identification of bacteria in bronchoalveolar lavage fluid from children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18263800" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29522532" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Fluctuations in airway bacterial communities associated with clinical states and disease stages in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12762292" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Infection control recommendations for patients with cystic fibrosis: Microbiology, important pathogens, and infection control practices to prevent patient-to-patient transmission.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19914445" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Cystic Fibrosis Foundation evidence-based guidelines for management of infants with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27009033" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Clinical Practice Guidelines From the Cystic Fibrosis Foundation for Preschoolers With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25425629" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Pseudomonas aeruginosa in cystic fibrosis patients with G551D-CFTR treated with ivacaftor.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31319678" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Ivacaftor Is Associated with Reduced Lung Infection by Key Cystic Fibrosis Pathogens. A Cohort Study Using National Registry Data.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31604026" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Changes in Airway Microbiome and Inflammation with Ivacaftor Treatment in Patients with Cystic Fibrosis and the G551D Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23540878" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20729233" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Controlled trial of cycled antibiotic prophylaxis to prevent initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32997797" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Prophylactic anti-staphylococcal antibiotics for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11953726" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Antibiotic prophylaxis in infants and young children with cystic fibrosis: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29035090" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Early Respiratory Bacterial Detection and Antistaphylococcal Antibiotic Prophylaxis in Young Children with Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17647287" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Approach to eradication of initial Pseudomonas aeruginosa infection in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25549030" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Cystic Fibrosis Foundation pulmonary guideline. pharmacologic approaches to prevention and eradication of initial Pseudomonas aeruginosa infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21893650" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37268599" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19996339" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Treatment of early Pseudomonas aeruginosa infection in patients with cystic fibrosis: the ELITE trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22379071" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a randomised multicentre study comparing two different protocols.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25972024" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29685813" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Eradication of early P. aeruginosa infection in children&lt;7 years of age with cystic fibrosis: The early study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28189634" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25091537" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29890086" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Azithromycin for Early Pseudomonas Infection in Cystic Fibrosis. The OPTIMIZE Randomized Trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33007285" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27378061" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Eradication of methicillin resistant Staphylococcus aureus detected for the first time in cystic fibrosis: A single center observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25683032" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Eradication of respiratory tract MRSA at a large adult cystic fibrosis centre.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27852955" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Microbiological efficacy of early MRSA treatment in cystic fibrosis in a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30030966" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Interventions for the eradication of meticillin-resistant Staphylococcus aureus (MRSA) in people with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30901344" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Methicillin-resistant Staphylococcus aureus eradication in cystic fibrosis patients: A randomized multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30131297" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Eradication of persistent methicillin-resistant Staphylococcus aureus infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36373968" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12480612" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24856775" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : European Cystic Fibrosis Society Standards of Care: Best Practice guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27233377" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25496726" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27720321" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Continuous alternating inhaled antibiotic therapy in CF: A single center retrospective analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8879776" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Antibiotic susceptibility of multiply resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis, including candidates for transplantation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Relevance of established susceptibility breakpoints to clinical efficacy of inhaled antibiotic therapies in cystic fibrosis
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17761616" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35089650" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Cystic Fibrosis Foundation otolaryngology care multidisciplinary consensus recommendations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21955231" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21075062" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26709158" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : One-year safety and efficacy of tobramycin powder for inhalation in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9878641" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11796432" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Long-term benefits of inhaled tobramycin in adolescent patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10191222" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Effect of chronic intermittent administration of inhaled tobramycin on respiratory microbial flora in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15463834" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : The long-term use of inhaled tobramycin in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11921456" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21815282" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Reduced mortality in cystic fibrosis patients treated with tobramycin inhalation solution.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18658109" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19420195" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20672296" id="rid87" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          88 : An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21441078" id="rid88" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          89 : Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15705991" id="rid89" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          90 : Bronchial constriction and inhaled colistin in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3301785" id="rid90" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          91 : Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23135343" id="rid91" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          92 : Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12358344" id="rid92" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          93 : A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16807142" id="rid93" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          94 : Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22985692" id="rid94" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          95 : Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24476418" id="rid95" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          96 : Azithromycin may antagonize inhaled tobramycin when targeting Pseudomonas aeruginosa in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28025037" id="rid96" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          97 : Impact of azithromycin on the clinical and antimicrobial effectiveness of tobramycin in the treatment of cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35448933" id="rid97" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          98 : The Pitfalls of Polypharmacy and Precision Medicine in Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1656866" id="rid98" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          99 : Persistence mechanisms in Pseudomonas aeruginosa from cystic fibrosis patients undergoing ciprofloxacin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8290742" id="rid99" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          100 : Regular three monthly oral ciprofloxacin in adult cystic fibrosis patients infected with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14734689" id="rid100" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          101 : Cystic fibrosis adult care: consensus conference report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6637463" id="rid101" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          102 : Frequent antibiotic therapy improves survival of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786481" id="rid102" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          103 : Elective versus symptomatic intravenous antibiotic therapy for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770814" id="rid103" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          104 : Elective versus symptomatic antibiotic treatment in cystic fibrosis patients with chronic Pseudomonas infection of the lungs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1417051" id="rid104" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          105 : The value of serum IgG titres against Pseudomonas aeruginosa in the management of early pseudomonal infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10770811" id="rid105" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          106 : Maintenance treatment of chronic pseudomonas aeruginosa infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29992775" id="rid106" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          107 : The myriad challenges of respiratory fungal infection in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10696856" id="rid107" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          108 : Diagnosis of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11934714" id="rid108" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          109 : Intracutaneous tests with recombinant allergens in cystic fibrosis patients with allergic bronchopulmonary aspergillosis and Aspergillus allergy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12975753" id="rid109" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          110 : Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31173402" id="rid110" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          111 : Antifungal prophylaxis in lung transplant: A survey of United States' transplant centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8275769" id="rid111" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          112 : Allergic bronchopulmonary aspergillosis in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16959918" id="rid112" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          113 : Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30275132" id="rid113" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          114 : Aspergillus and progression of lung disease in children with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35790954" id="rid114" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          115 : Persistent Aspergillus fumigatus infection in cystic fibrosis: impact on lung function and role of treatment of asymptomatic colonization-a registry-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19567494" id="rid115" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          116 : The effect of chronic infection with Aspergillus fumigatus on lung function and hospitalization in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22563440" id="rid116" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          117 : Treatment of Aspergillus fumigatus in patients with cystic fibrosis: a randomized, placebo-controlled pilot study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28795298" id="rid117" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          118 : Pharmacokinetics of Azole Antifungals in Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23460012" id="rid118" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          119 : Nontuberculous mycobacteria in patients with cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32950412" id="rid119" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          120 : Low rates of macrolide-resistant Mycobacterium avium complex in cystic fibrosis despite chronic azithromycin therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30724835" id="rid120" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          121 : Improved Clinical Outcome After Treatment of Mycobacterium abscessus Complex Pulmonary Disease in Children With Cystic Fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24251858" id="rid121" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          122 : Clinical significance of a first positive nontuberculous mycobacteria culture in cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26846823" id="rid122" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          123 : Should all adult cystic fibrosis patients with repeated nontuberculous mycobacteria cultures receive specific treatment? A 10-year case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17178340" id="rid123" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          124 : Mycobacterium abscessus infections in lung transplant recipients: the international experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30924986" id="rid124" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          125 : Management and clinical outcomes after lung transplantation in patients with pre-transplant Mycobacterium abscessus infection: A single center experience.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29788939" id="rid125" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          126 : NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15184530" id="rid126" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          127 : Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24452167" id="rid127" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          128 : Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20081099" id="rid128" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          129 : Clinical outcome for cystic fibrosis patients infected with transmissible pseudomonas aeruginosa: an 8-year prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25025126" id="rid129" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          130 : Infection prevention and control guideline for cystic fibrosis: 2013 update.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23541540" id="rid130" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          131 : Whole-genome sequencing to identify transmission of Mycobacterium abscessus between patients with cystic fibrosis: a retrospective cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28930641" id="rid131" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          132 : Face Masks and Cough Etiquette Reduce the Cough Aerosol Concentration of Pseudomonas aeruginosa in People with Cystic Fibrosis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
